One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Dynavax Technologies Corporation logo
Dynavax Technologies Corporation DVAX
report update icon

Quarterly report 2025-Q3
added 06-13-2026

Dynavax Technologies Corporation Financial Ratios 2024-2008 | DVAX

Brief overview of Dynavax Technologies Corporation's market valuation

Current figures are compared with the company's own five-year history for 2020–2024.

Key multiples at the end of the period are P/E 63.34x (median 19.66x), P/S 6.24x (median 6.24x), P/B 2.9x (median 2.9x). On average, this basket is 19% above its own five-year medians. The market is pricing in elevated future expectations.

Earnings yield calculated as 1/P/E is about 1.6%, showing current profit per unit of share price.

End-period return metrics are ROE 4.6%, ROA 2.8%, ROCE -0.7%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.

The PEG ratio is 3.17x; investors pay a high price per unit of expected growth.

A shorter cycle, from 1,602.1 days to 459 days, indicates faster release of cash from operations.

Valuation takeaway

Dynavax Technologies Corporation's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.

Annual Financial Ratios Dynavax Technologies Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

63.3 -251.9 4.6 19.7 -8.4 -2.4 -4.3 -9.1 -1.3 -7.4 -5.0 -5.2 -7.4 -9.1 - - -

P/S

6.2 6.9 1.9 3.4 13.7 10.2 83.8 2638.7 13.4 195.6 40.7 30.7 53.0 20.5 - - -

EPS

0.2 -0.1 2.3 0.6 -0.8 -2.2 -2.5 -1.8 -2.9 -3.2 -3.5 -0.4 -0.4 -0.4 -0.7 -0.8 -

EV (Enterprise Value)

2.02 B 1.83 B 1.56 B 1.89 B 898 M 590 M 786 M 856 M 144 M 777 M 438 M 341 M 532 M 445 M -22.5 M -36.7 M -28.1 M

EBITDA per Share

- -0.25 2.27 1.19 -0.64 -1.39 -2.23 -1.75 -2.82 -3.15 -3.42 -3.32 -3.89 -3.78 -0.56 - -

EV/EBITDA

4006.3 -56.1 5.4 12.8 -11.9 -5.0 -5.3 -9.1 -1.1 -7.2 -4.6 -4.9 -7.6 -9.0 0.5 2.8 -

PEG

-0.69 3.17 -0.09 -0.25 0.37 -0.15 0.11 -0.24 -0.13 -1.28 -0.54 -0.71 1.44 -0.21 - - -

P/B

2.9 2.6 2.3 6.8 10.8 43.4 10.9 4.3 1.7 4.2 4.5 1.9 4.5 4.4 - - -

P/CF

26.0 16.0 21.7 4.5 -6.9 -2.4 -4.7 -11.0 -1.3 -8.0 -6.0 -5.7 -11.0 -9.2 - - -

ROE %

4.58 -1.03 50.46 34.50 -128.19 -1840.77 -251.96 -47.68 -126.06 -57.08 -90.29 -35.81 -60.92 -48.66 -109.97 -479.38 -

ROA %

2.77 -0.64 29.74 7.38 -21.30 -54.68 -75.35 -43.49 -102.52 -49.30 -65.60 -32.61 -50.05 -36.24 -68.02 - -

ROCE %

-0.69 -5.95 48.80 60.48 -116.49 -53.75 -88.70 -46.57 -123.50 -55.94 -77.37 -35.29 -55.99 -44.51 -91.32 -237.06 -

Current Ratio

2.5 2.7 2.4 1.3 1.2 3.9 4.6 10.7 4.5 6.9 6.3 11.9 6.7 4.6 - - -

DSO

56.5 145.9 66.0 57.7 123.7 92.1 164.9 953.2 44.4 125.6 24.1 52.8 37.8 160.9 7.6 - -

DIO

455.3 410.1 84.1 131.5 1679.8 778.1 318.5 - - - - - - - - - -

DPO

52.8 30.8 4.0 6.2 201.4 174.7 88.4 - - - - - - - - - -

Operating Cycle

511.8 556.0 150.1 189.1 1803.5 870.2 483.5 - - - - - - - 7.6 - -

Cash Conversion Cycle

459.0 525.3 146.0 182.9 1602.1 695.5 395.1 - - - - - - - 7.6 - -

All numbers in USD currency

Quarterly Financial Ratios Dynavax Technologies Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.23 0.16 -0.77 - 0.13 0.09 -0.07 - 0.11 0.03 -0.19 - 0.5 1.02 0.26 - -0.24 0.04 0.01 - 0.04 -0.53 -0.15 -0.44 -0.49 -0.66 -0.62 -0.64 -0.65 -0.63 -0.63 -0.45 -0.38 -0.41 -0.6 -0.56 -0.9 -0.75 -0.7 -0.7 -0.82 -0.8 -0.97 -0.85 -1.13 -0.94 -0.53 -0.91 -0.09 -0.09 -0.11 -0.11 -0.1 -0.09 -0.11 -0.03 -0.12 -0.09 -0.16

EBITDA per Share

0.21 0.14 -0.18 - - - -0.13 - - - -0.23 - 0.51 1.01 0.25 - 0.17 0.08 0.26 - -0.1 -0.22 -0.21 - -0.3 -0.55 -0.57 - -0.58 -0.59 -0.61 - -0.35 -0.38 -0.59 - -0.86 -0.74 -0.7 - -0.75 -0.77 -0.96 - -1.11 -0.92 -0.52 - -0.08 -0.09 -0.11 - -0.09 -0.08 -0.1 - -0.11 -0.08 -0.15

ROE %

-6.69 -9.96 -15.16 2.94 5.31 3.32 -2.77 -1.36 11.39 39.48 50.31 54.63 12.56 5.18 -24.38 -35.81 -28.32 -74.12 -100.95 -101.84 -545.22 -956.32 -1383.68 -1840.77 -1460.77 -1121.43 -668.74 -251.96 -202.32 -149.15 -96.79 -47.68 -58.32 -86.12 -108.43 -126.06 -116.04 -93.25 -73.37 -57.08 -64.91 -78.48 -90.53 -90.29 -75.12 -53.85 -38.41 -35.81 -46.70 -53.78 -57.72 -60.92 -47.30 -47.05 -44.54 -48.66 -15.25 -10.65 -18.49

ROA %

-3.62 -5.34 -8.27 1.89 3.36 2.07 -1.56 -0.67 5.71 7.50 4.04 6.55 7.24 0.86 1.04 -2.22 -0.97 -12.48 -16.74 -16.92 -30.09 -43.33 -44.03 -54.68 -60.46 -67.69 -71.09 -75.35 -68.93 -59.83 -50.41 -43.49 -50.78 -72.30 -89.44 -102.52 -95.10 -77.37 -61.83 -49.30 -53.01 -60.67 -67.70 -65.60 -55.87 -41.97 -32.44 -32.61 -40.93 -46.00 -48.42 -50.05 -38.53 -37.16 -34.28 -36.24 -11.36 -7.93 -13.77

ROCE %

3.93 0.76 -5.04 -0.58 0.26 -1.81 -7.98 -5.11 7.16 36.64 47.93 53.29 77.07 75.81 74.08 63.37 39.82 -23.72 -67.63 -96.22 -465.69 -912.23 -1329.09 -1296.19 -1357.87 -1048.88 -639.54 -182.92 -194.14 -142.65 -94.91 -34.16 -73.21 -94.79 -115.20 -102.45 -117.65 -91.02 -72.36 -41.76 -71.69 -81.23 -82.71 -68.57 -76.92 -56.14 -42.62 -28.72 -43.61 -48.01 -52.66 -41.45 -56.29 -51.51 -56.70 -42.89 -14.84 -10.11 -17.95

Current Ratio

2.3 2.2 2.3 2.5 2.8 2.7 2.7 2.7 2.6 2.6 2.4 2.4 2.0 - 1.4 1.3 1.1 1.1 1.3 1.2 1.2 1.2 1.2 1.0 1.0 1.0 1.0 1.4 1.4 1.4 1.4 11.4 11.4 11.4 11.4 5.4 5.4 5.4 5.4 7.3 7.3 7.3 7.3 3.7 3.7 3.7 3.7 11.2 11.2 11.2 11.2 5.6 5.6 5.6 5.6 3.9 3.9 - -

DSO

68.8 60.0 67.1 - 76.4 65.4 76.2 - 58.8 109.8 240.0 - - - - - 129.1 164.2 58.4 - 196.2 775.0 131.8 76.7 76.7 97.7 99.5 63.6 231.3 269.5 1260.4 3710.8 1470.3 742.2 677.0 16.8 755.9 43.2 123.9 170.3 69.9 46.1 119.0 29.1 30.0 21.8 30.7 52.1 50.7 43.8 57.6 50.8 31.9 34.2 204.5 76.1 740.5 119.6 -

DIO

471.9 487.9 478.7 - 435.4 473.1 478.9 - 353.5 373.4 363.3 - 76.3 43.2 160.3 - 116.7 - 245.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

21.1 22.9 44.4 - 40.6 26.6 31.9 - 22.0 35.5 32.6 - 2.3 11.1 26.0 - 11.9 - 12.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

540.7 548.0 545.7 - 511.8 538.5 555.0 - 412.3 483.2 603.3 - 76.3 43.2 160.3 - 245.8 164.2 303.9 - 196.2 775.0 131.8 76.7 76.7 97.7 99.5 63.6 231.3 269.5 1260.4 3710.8 1470.3 742.2 677.0 16.8 755.9 43.2 123.9 170.3 69.9 46.1 119.0 29.1 30.0 21.8 30.7 52.1 50.7 43.8 57.6 50.8 31.9 34.2 204.5 76.1 740.5 119.6 -

Cash Conversion Cycle

519.6 525.1 501.4 - 471.2 511.9 523.1 - 390.4 447.6 570.7 - 74.1 32.2 134.2 - 233.9 164.2 292.0 - 196.2 775.0 131.8 76.7 76.7 97.7 99.5 63.6 231.3 269.5 1260.4 3710.8 1470.3 742.2 677.0 16.8 755.9 43.2 123.9 170.3 69.9 46.1 119.0 29.1 30.0 21.8 30.7 52.1 50.7 43.8 57.6 50.8 31.9 34.2 204.5 76.1 740.5 119.6 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Dynavax Technologies Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
- - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
- - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
- 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
- - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
- 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA